Host-Environment Interactions in Pulmonary Fibrosis

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a progressive scarring disease of the pulmonary parenchyma, leading to respiratory failure and death. Several epidemiological and theoretical observations link the pathogenesis of this disease to environmental injury to the lungs. We discuss the theoretical framework of this hypothesis and we present data in support of the concept that genetic and nongenetic host susceptibility may interact with repetitive environmental injury to lead to IPF.

KEYWORDS

Idiopathic pulmonary fibrosis - host susceptibility - environmental triggers

REFERENCES

• 1 Car B D, Meloni F, Luisetti M, Semenzato G, Gialdroni-Grassi G, Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis.  Am J Respir Crit Care Med. 1994;  149(3 Pt 1) 655-659
• 2 Southcott A M, Jones K P, Li D et al.. Interleukin-8: differential expression in lone fibrosing alveolitis and systemic sclerosis.  Am J Respir Crit Care Med. 1995;  151 1604-1612
• 3 Tsoutsou P G, Gourgoulianis K I, Petinaki E et al.. Cytokine levels in the sera of patients with idiopathic pulmonary fibrosis.  Respir Med. 2006;  100 938-945 , Epub 2005 Oct 2019
• 4 Ziegenhagen M W, Zabel P, Zissel G, Schlaak M, Muller-Quernheim J. Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity.  Am J Respir Crit Care Med. 1998;  157(3 Pt 1) 762-768
• 5 Adams P F, Hendershot G E, Marano M A. Current estimates from the National Health Interview Survey, 1996.  Vital Health Stat 10. 1999;  200 1-203
• 6 Garantziotis S, Steele M P, Schwartz D A. Pulmonary fibrosis: thinking outside of the lung.  J Clin Invest. 2004;  114 319-321
• 7 Baumgartner K B, Samet J M, Stidley C A, Colby T V, Waldron J A. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1997;  155 242-248
• 8 Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.  Lancet. 1996;  347 284-289
• 9 Hubbard R, Cooper M, Antoniak M et al.. Risk of cryptogenic fibrosing alveolitis in metal workers.  Lancet. 2000;  355 466-467
• 10 Iwai K, Mori T, Yamada N, Yamaguchi M, Hosoda Y. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure.  Am J Respir Crit Care Med. 1994;  150 670-675
• 11 Coultas D B, Zumwalt R E, Black W C, Sobonya R E. The epidemiology of interstitial lung diseases.  Am J Respir Crit Care Med. 1994;  150 967-972
• 12 Johnston I, Britton J, Kinnear W, Logan R. Rising mortality from cryptogenic fibrosing alveolitis.  BMJ. 1990;  301 1017-1021
• 13 Selikoff I J, Hammond E C, Seidman H. Mortality experience of insulation workers in the United States and Canada, 1943-1976.  Ann NY Acad Sci. 1979;  330 91-116
• 14 Marshall R P, Puddicombe A, Cookson W O, Laurent G J. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom.  Thorax. 2000;  55 143-146
• 15 Steele M P, Speer M C, Loyd J E et al.. Clinical and pathologic features of familial interstitial pneumonia.  Am J Respir Crit Care Med. 2005;  172 1146-1152 , Epub 2005 Aug 1118
• 16 American Thoracic Society . Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).  Am J Respir Crit Care Med. 2000;  161(2 Pt 1) 646-664
• 17 Rossi G A, Szapiel S, Ferrans V J, Crystal R G. Susceptibility to experimental interstitial lung disease is modified by immune- and non-immune-related genes.  Am Rev Respir Dis. 1987;  135 448-455
• 18 Callis A H, Sohnle P G, Mandel G S, Wiessner J, Mandel N S. Kinetics of inflammatory and fibrotic pulmonary changes in a murine model of silicosis.  J Lab Clin Med. 1985;  105 547-553
• 19 Reinhard M C, Mirand E A, Goltz H L, Hoffman J G. Mouse-strain differences in response to radiation.  Proc Soc Exp Biol Med. 1954;  85 367-370
• 20 Schwartz D A, Van Fossen D S, Davis C S et al.. Determinants of progression in idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1994;  149(2 Pt 1) 444-449
• 21 Pleis J R, Schiller J S, Benson V. Summary health statistics for U.S. adults: National Health Interview Survey, 2000.  Vital Health Stat 10. 2003;  215 1-132
• 22 Adams P F, Schoenborn C A, Moss A J, Warren C W, Kann L. Health-risk behaviors among our nation's youth: United States, 1992.  Vital Health Stat 10. 1995;  192 1-51
• 23 Glazer C S, Newman L S. Occupational interstitial lung disease.  Clin Chest Med. 2004;  25 467-478
• 24 Baumgartner K B, Samet J M, Coultas D B et al.. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers.  Am J Epidemiol. 2000;  152 307-315
• 25 Miyake Y, Sasaki S, Yokoyama T et al.. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan.  Ann Occup Hyg. 2005;  49 259-265 , Epub 2005 Jan 2007
• 26 Rimal B, Greenberg A K, Rom W N. Basic pathogenetic mechanisms in silicosis: current understanding.  Curr Opin Pulm Med. 2005;  11 169-173
• 27 Dai J, Gilks B, Price K, Churg A. Mineral dusts directly induce epithelial and interstitial fibrogenic mediators and matrix components in the airway wall.  Am J Respir Crit Care Med. 1998;  158 1907-1913
• 28 Hubbs A F, Minhas N S, Jones W et al.. Comparative pulmonary toxicity of 6 abrasive blasting agents.  Toxicol Sci. 2001;  61 135-143
• 29 Schapira R M, Ghio A J, Effros R M et al.. Hydroxyl radical production and lung injury in the rat following silica or titanium dioxide instillation in vivo.  Am J Respir Cell Mol Biol. 1995;  12 220-226
• 30 Tang Y W, Johnson J E, Browning P J et al.. Herpesvirus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis.  J Clin Microbiol. 2003;  41 2633-2640
• 31 Yonemaru M, Kasuga I, Kusumoto H et al.. Elevation of antibodies to cytomegalovirus and other herpes viruses in pulmonary fibrosis.  Eur Respir J. 1997;  10 2040-2045
• 32 Egan J J, Stewart J P, Hasleton P S, Arrand J R, Carroll K B, Woodcock A A. Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.  Thorax. 1995;  50 1234-1239
• 33 Stewart J P, Egan J J, Ross A J et al.. The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1999;  159(4 Pt 1) 1336-1341
• 34 Cohen J I. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases.  Semin Hematol. 2003;  40 116-123
• 35 Dawson C W, Rickinson A B, Young L S. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation.  Nature. 1990;  344 777-780
• 36 Tsukamoto K, Hayakawa H, Sato A, Chida K, Nakamura H, Miura K. Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis.  Thorax. 2000;  55 958-961
• 37 Lok S S, Haider Y, Howell D, Stewart J P, Hasleton P S, Egan J J. Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice.  Eur Respir J. 2002;  20 1228-1232
• 38 Mora A L, Woods C R, Garcia A et al.. Lung infection with gamma-herpesvirus induces progressive pulmonary fibrosis in Th2-biased mice.  Am J Physiol Lung Cell Mol Physiol. 2005;  289 L711-721 , Epub 2005 Feb 2025
• 39 Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway.  Nature. 1999;  397 710-713
• 40 Chung M P, Monick M M, Hamzeh N Y, Butler N S, Powers L S, Hunninghake G W. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis.  Am J Respir Cell Mol Biol. 2003;  29(3 Pt 1) 375-380 , Epub 2003 Apr 2003
• 41 Ueda T, Ohta K, Suzuki N et al.. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus.  Am Rev Respir Dis. 1992;  146 266-268
• 42 Ferri C, La Civita L, Fazzi P et al.. Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection.  Br J Rheumatol. 1997;  36 360-365
• 43 Irving W L, Day S, Johnston I D. Idiopathic pulmonary fibrosis and hepatitis C virus infection.  Am Rev Respir Dis. 1993;  148(6 Pt 1) 1683-1684
• 44 Idilman R, Cetinkaya H, Savas I et al.. Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C.  J Med Virol. 2002;  66 34-39
• 45 Yamaguchi S, Kubo K, Fujimoto K, Honda T, Sekiguchi M, Sodeyama T. Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha.  Thorax. 1997;  52 33-37
• 46 Kuwano K, Nomoto Y, Kunitake R et al.. Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction.  Eur Respir J. 1997;  10 1445-1449
• 47 Hubbard R, Venn A, Smith C, Cooper M, Johnston I, Britton J. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study.  Am J Respir Crit Care Med. 1998;  157(3 Pt 1) 743-747
• 48 Musk A W, Pollard J A. Pindolol and pulmonary fibrosis.  BMJ. 1979;  2 581-582
• 49 Erwteman T M, Braat M C, van Aken W G. Interstitial pulmonary fibrosis: a new side effect of practolol.  BMJ. 1977;  2 297-298
• 50 Zevin S, Benowitz N L. Drug interactions with tobacco smoking: an update.  Clin Pharmacokinet. 1999;  36 425-438
• 51 Patti M G, Tedesco P, Golden J et al.. Idiopathic pulmonary fibrosis: how often is it really idiopathic?.  J Gastrointest Surg. 2005;  9 1053-1056 discussion 1056-1058
• 52 Raghu G, Freudenberger T D, Yang S et al.. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis.  Eur Respir J. 2006;  27 136-142
• 53 Tobin R W, Pope II C E, Pellegrini C A, Emond M J, Sillery J, Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis.  Am J Respir Crit Care Med. 1998;  158 1804-1808
• 54 Brennan N J, Morris A J, Green M. Thoracoabdominal mechanics during tidal breathing in normal subjects and in emphysema and fibrosing alveolitis.  Thorax. 1983;  38 62-66
• 55 Todisco T. Thoracoabdominal mechanics in dyspnea.  Respiration. 1981;  42 77-83
• 56 Schwartz D J, Wynne J W, Gibbs C P, Hood C I, Kuck E J. The pulmonary consequences of aspiration of gastric contents at pH values greater than 2.5  Am Rev Respir Dis. 1980;  121 119-126
• 57 Popper H, Juettner F, Pinter J. The gastric juice aspiration syndrome (Mendelson syndrome): aspects of pathogenesis and treatment in the pig.  Virchows Arch A Pathol Anat Histopathol. 1986;  409 105-117
• 58 Raghu G, Yang S T, Spada C, Hayes J, Pellegrini C A. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series.  Chest. 2006;  129 794-800
• 59 Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.  Thorax. 1980;  35 171-180
• 60 Carrington C B, Gaensler E A, Coutu R E, FitzGerald M X, Gupta R G. Natural history and treated course of usual and desquamative interstitial pneumonia.  N Engl J Med. 1978;  298 801-809
• 61 Crystal R G, Fulmer J D, Roberts W C, Moss M L, Line B R, Reynolds H Y. Idiopathic pulmonary fibrosis: clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects.  Ann Intern Med. 1976;  85 769-788
• 62 Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis.  Rheumatology (Oxford). 2002;  41 676-679
• 63 Bouros D, Wells A U, Nicholson A G et al.. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.  Am J Respir Crit Care Med. 2002;  165 1581-1586
• 64 Dong C, Zhu S, Wang T et al.. Deficient Smad7 expression: a putative molecular defect in scleroderma.  Proc Natl Acad Sci USA. 2002;  99 3908-3913
• 65 Kikuchi K, Kadono T, Ihn H et al.. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1.  J Invest Dermatol. 1995;  105 128-132
• 66 Nicholson A G, Florio R, Hansell D M et al.. Pulmonary involvement by Niemann-Pick disease: a report of six cases.  Histopathology. 2006;  48 596-603
• 67 Mendelson D S, Wasserstein M P, Desnick R J et al.. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing.  Radiology. 2006;  238 339-345 , Epub 2005 Nov 2022
• 68 Knight S, Vulliamy T, Copplestone A, Gluckman E, Mason P, Dokal I. Dyskeratosis Congenita (DC) Registry: identification of new features of DC.  Br J Haematol. 1998;  103 990-996
• 69 Lawson W E, Grant S W, Ambrosini V et al.. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF.  Thorax. 2004;  59 977-980
• 70 Lawson W E, Polosukhin V V, Stathopoulos G T et al.. Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin.  Am J Pathol. 2005;  167 1267-1277
• 71 Thomas A Q, Lane K, Phillips III J et al.. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred.  Am J Respir Crit Care Med. 2002;  165 1322-1328
• 72 Liu T, Hu B, Chung M J, Ullenbruch M, Jin H, Phan S H. Telomerase regulation of myofibroblast differentiation.  Am J Respir Cell Mol Biol. 2006;  34 625-633 , Epub 2006 Jan 2019
• 73 Collins K, Mitchell J R. Telomerase in the human organism.  Oncogene. 2002;  21 564-579
• 74 Mu X C, Staiano-Coico L, Higgins P J. Increased transcription and modified growth state-dependent expression of the plasminogen activator inhibitor type-1 gene characterize the senescent phenotype in human diploid fibroblasts.  J Cell Physiol. 1998;  174 90-98
• 75 Mu X C, Higgins P J. Differential growth state-dependent regulation of plasminogen activator inhibitor type-1 expression in senescent IMR-90 human diploid fibroblasts.  J Cell Physiol. 1995;  165 647-657